stormvogel schreef op 19 juli 2011 08:58:
Other products
Sales of Kepivance® fell by 37% to SEK 17.7 M (28.1) and by 25% when adjusted for currency effects. The reduction is mainly related to Europe where the regulatory authority, the EMA, decided in 2010 to impose a restriction on the approved indication. Sales of Kepivance® stabilized during the quarter, however, after a sharp decline during the second half of 2010.
Sales of Ammonaps® fell by 1% to SEK 17.4 M (17.5) but increased by 7% when adjusted for currency effects. Sales were higher than in the first quarter of the year which was negatively affected by the manufacturing and delivery problems of Sobi’s partner in the US. These problems were solved in the second quarter.
Sales of Yondelis® increased by 39% to SEK 12.2 M (8.8) and by 45% when adjusted for currency effects. The positive trend in sales is the result of increased sales and marketing activities and an increase in the use of the product for the two approved indications.
Sales of Multiferon® increased by 104% to SEK 2.5 M (1.2) and by 120% when adjusted for currency effects. The increase is mainly attributable to Central and Eastern Europe and the Nordic region.
Other products also showed good growth.